AARD
Aardvark Therapeutics, Inc.
$3.59
-2.45%
$78.3M
No data for this timeframe.
Vol
Market Cap$78.3M
Cap SizeMicro Cap
Analyst ConsensusBuy (67%)
Inst. Holders7 funds
Inst. Value$13.1M
Inst. Activity6 buys / 0 sells
SEC Reports5
Press Releases2
Recent Activity
Sep 30, 2026
fda_pdufa
PDUFA: AARD — ARD-101 in Prader-Willi Syndrome — 2026-09-30
FDA target action date 2026-09-30 for AARD (Aardvark Therapeutics, Inc.). Drug: ARD-101. Indication:
May 7, 2026
SEC
Aardvark Therapeutics reported Q1 2026 net loss of $21.6M ($0.99 per share), missing consensus of $(0.91) by 8.8%. Both
8-K — Impact 6/10
Apr 6, 2026
SEC
Aardvark Therapeutics' S-3 shelf registration has become effective, allowing the company to raise up to $400 million thr
EFFECT — Impact 7/10
Apr 3, 2026
SEC
Aardvark Therapeutics is conducting an at-the-market equity offering of up to $150 million through Piper Sandler, just 1
424B5 — Impact 7/10
Feb 9, 2026
Insider
Jaiman Manasi sold 70,549 shares
Chief Medical Officer @ $0.00 ($0.00)
Feb 9, 2026
Insider
Sun Nelson sold 70,549 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 9, 2026
Insider
Lee Tien-Li sold 203,851 shares
Chief Executive Officer @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
717,430 shares ($9.4M)
Price Targets
$15.44
+331.4% upside
Strong Buy
Current $3.58
Low $3.00
Median $7.00
High $45.00
9 analysts
$3.00
$45.00
Analyst Ratings
6Strong Buy
6Buy
4Hold
2Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| May 15, 2026 | BTIG | DOWNGRADE | Buy → Neutral |
| May 15, 2026 | Morgan Stanley | DOWNGRADE | Equal-Weight → Underweight |
| Mar 24, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 2, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.87 ▲ +0.9% | $-1.06 — $-0.67 | -32% YoY | 8 |
| Next Q | $-0.87 ▼ -0.6% | $-1.13 — $-0.58 | -16% YoY | 8 |
| Current FY | $-3.65 ▼ -6.7% | $-4.40 — $-2.83 | -25% YoY | 9 |
| Next FY | $-3.24 ▲ +6.6% | $-5.99 — $-1.59 | 11% YoY | 8 |
Latest Reports
BEARISH
Press
8/10
Aardvark Therapeutics announced the FDA placed a full clinical hold on its IND for ARD-101, covering the Phase 3 HERO tr
May 14, 2026
BEARISH
8-K
6/10
Aardvark Therapeutics reported Q1 2026 net loss of $21.6M ($0.99 per share), missing consensus of $(0.91) by 8.8%. Both
May 7, 2026
BEARISH
EFFECT
7/10
Aardvark Therapeutics' S-3 shelf registration has become effective, allowing the company to raise up to $400 million thr
Apr 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $9.4M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.7M | DOUBLED |
| MORGAN STANLEY | $1.0M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $413.9K | DOUBLED |
| BANK OF AMERICA CORP | $402.4K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 9, 2026 | Jaiman Manasi | A | $0.00 |
| Feb 9, 2026 | Sun Nelson | A | $0.00 |
| Feb 9, 2026 | Lee Tien-Li | A | $0.00 |
7 institutional holders with $13.1M total value (1,001,699 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 717,430 | $9.4M | 71.6% | ADD +29.1% |
| 2 | TWO SIGMA INVESTMENTS, LP | 128,786 | $1.7M | 12.9% | DOUBLED +102.6% |
| 3 | MORGAN STANLEY | 77,954 | $1.0M | 7.8% | DOUBLED +664.1% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 31,533 | $413.9K | 3.1% | DOUBLED +121.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 30,660 | $402.4K | 3.1% | ADD +28.1% |
| 6 | WELLS FARGO & COMPANY/MN | 14,080 | $184.8K | 1.4% | DOUBLED +259.5% |
| 7 | FMR LLC | 1,256 | $16.5K | 0.1% | DOUBLED +246.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 555,721 | 717,430 | +29.1% | $9.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 63,569 | 128,786 | +102.6% | $1.7M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 14,240 | 31,533 | +121.4% | $413.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 23,930 | 30,660 | +28.1% | $402.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 3,917 | 14,080 | +259.5% | $184.8K | 2025-Q4 |
| FMR LLC | DOUBLED | 363 | 1,256 | +246.0% | $16.5K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 8,960 | 68,462 | +664.1% | $909.9K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 63,569 | — | $844.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 7,989 | 23,930 | +199.5% | $318.0K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 165,491 | 460,977 | +178.6% | $6.2M | 2025-Q2 |
| UBS Group AG | DOUBLED | 14,705 | 51,924 | +253.1% | $702.0K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 14,240 | — | $192.5K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 2,218 | 8,960 | +304.0% | $121.1K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 4,620 | 7,989 | +72.9% | $108.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 3,239 | — | $43.8K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 15,424 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 1,274,084 | — | $9.4M | 2025-Q1 |
| VANGUARD GROUP INC | NEW | — | 165,491 | — | $1.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 15,424 | — | $115.8K | 2025-Q1 |
| UBS Group AG | NEW | — | 14,705 | — | $110.4K | 2025-Q1 |
| MORGAN STANLEY | NEW | — | 2,218 | — | $16.7K | 2025-Q1 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Jaiman Manasi | Chief Medical Officer | A | 70,549 | $0.00 | $0.00 |
| Feb 9, 2026 | Sun Nelson | Chief Financial Officer | A | 70,549 | $0.00 | $0.00 |
| Feb 9, 2026 | Lee Tien-Li | Chief Executive Officer | A | 203,851 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 1 neutral. Avg impact: 6.2/10.
BEARISH
8-K
6/10
Aardvark Therapeutics reported Q1 2026 net loss of $21.6M ($0.99 per share), missing consensus of $(
May 7, 2026
BEARISH
EFFECT
7/10
Aardvark Therapeutics' S-3 shelf registration has become effective, allowing the company to raise up
Apr 6, 2026
BEARISH
424B5
7/10
Aardvark Therapeutics is conducting an at-the-market equity offering of up to $150 million through P
Apr 3, 2026
NEUTRAL
8-K
4/10
Aardvark Therapeutics entered into an equity distribution agreement with Piper Sandler & Co. to pote
Mar 24, 2026
BEARISH
S-3
7/10
Aardvark Therapeutics has filed an S-3 shelf registration allowing it to raise up to $400 million th
Mar 23, 2026
Current analyst consensus: Buy (67% buy). Based on 18 analysts: 6 strong buy, 6 buy, 4 hold, 2 sell, 0 strong sell.
Analyst Price Targets
$15.44 mean target
+331.4% upside
Strong Buy (2.25)
$3.00 Low
$45.00 High
| Metric | Value |
|---|---|
| Current Price | $3.58 |
| Target Low | $3.00 |
| Target Mean | $15.44 |
| Target Median | $7.00 |
| Target High | $45.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (2.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.87 | $-1.06 | $-0.67 | -31.6% | +0.9% | 1↑ 4↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.87 | $-1.13 | $-0.58 | -15.8% | -0.6% | 1↑ 4↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-3.65 | $-4.40 | $-2.83 | -24.6% | -6.7% | 0↑ 7↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-3.24 | $-5.99 | $-1.59 | 11.3% | +6.6% | 3↑ 4↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.869 | |
| 7d ago | $-0.870 | +0.001 |
| 30d ago | $-0.876 | +0.007 |
| 60d ago | $-0.933 | +0.065 |
| 90d ago | $-0.947 | +0.078 |
8 analyst firms have rated this stock: 0 upgrades, 6 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| May 15, 2026 | BTIG | DOWNGRADE | Buy | Neutral |
| May 15, 2026 | Morgan Stanley | DOWNGRADE | Equal-Weight | Underweight |
| Mar 24, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 2, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 2, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Mar 2, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Mar 2, 2026 | Stifel | DOWNGRADE | Buy | Hold |
| Mar 2, 2026 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Feb 10, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 23, 2025 | Oppenheimer | INITIATE | — | Outperform |
| Dec 12, 2025 | William Blair | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 6 | 4 | 2 | 0 | 67% | |
| May 1, 2026 | 7 | 6 | 5 | 0 | 0 | 72% | |
| Apr 1, 2026 | 7 | 6 | 5 | 0 | 0 | 72% | |
| Mar 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Sep 30, 2026
fda_pdufa
PDUFA: AARD — ARD-101 in Prader-Willi Syndrome — 2026-09-30
FDA target action date 2026-09-30 for AARD (Aardvark Therapeutics, Inc.). Drug: ARD-101. Indication: Prader-Willi Syndrome. PDUFA target action date o
May 14, 2026
fda
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
<p>SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceuti
May 7, 2026
earnings
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><em>ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026</em></p>
Mar 23, 2026
earnings
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prade